This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by COUTINHO, E. M. Articles by KINCL, F. Search for Related Content PubMed Articles by COUTINHO, E. M. Articles by KINCL, F.

EXCRETION OF [6-¹⁴C]MEGESTROL ACETATE (6 METHYL-17 ACETOXYPREGNA-4,6 DIENE, 3,20 DIONE) RELEASED FROM SUBCUTANEOUS SILASTIC IMPLANTS IN WOMEN

The use of a subcutaneous inert capsule containing a progestational steroid has been proposed recently for long-term control of fertility. The results of pilot studies (Croxatto, Diaz, Vera, Etchart & Atria, 1969) indicate that, with this technique, it is possible to prevent conception without interfering with ovulation, apparently because the progestin is released slowly but continuously in very small amounts. It has been estimated that four to six silastic capsules (each containing 18 mg of megestrol acetate) would effectively prevent conception for 1 year. However, the basis for this estimate was derived from our clinical data alone (Tatum, Coutinho, Adeodato Filho & Sant'Ana, 1969) and for this reason the present investigation was undertaken. Here, the excretion rates of [6-¹⁴C]megestrol acetate are reported for post-menopausal women implanted with capsules containing the radioactive steroid in the same amount as in the capsules used for contraceptive purposes.

Dimethylpolysiloxane (Silastic 602-235